Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn how safe and well-tolerated mycophenolate mofetil (MMF)
is when given with abacavir (ABC). Another purpose is to see if adding MMF to ABC decreases
viral load (amount of HIV in the blood) more than ABC alone.
Many HIV-infected patients who have had heavy exposure to anti-HIV drugs and have experienced
treatment failure need new treatment combinations. One promising combination is ABC and MMF
as part of a drug combination. Laboratory studies show that MMF helps ABC destroy HIV in the
cells and further clinical testing is needed. MMF is not FDA-approved as a treatment for HIV
infection but has been approved by FDA to prevent rejection of organ transplants. Doses of
MMF tested in this study will be lower than those used to treat people with organ
transplants.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)